IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Claim check

A clinic success rate proves efficacy.

Outcome claims need denominator, follow-up window, definition of success, adverse-event reporting, conflicts, and independent review.

VERDICT Weak evidence

“A clinic success rate proves efficacy.”

Outcome claims need denominator, follow-up window, definition of success, adverse-event reporting, conflicts, and independent review.

Clinic observatory · Claims